カテゴリ： GlobalData, アイルランド, 企業調査

Jazz Pharmaceuticals Plc (JAZZ)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012282
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：90
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc (JAZZ) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 16
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 18
Venture Financing 19
Arrivo BioVentures Raises USD49 Million in Venture Financing 19
Alize Pharma Raises USD1.9 Million in Venture Financing 20
Alize Pharma Raises USD6.4 Million in Series A Financing 21
Celator Pharma Raises US$39 Million In Venture Financing 22
Alize Pharma Raises US$4 Million In Venture Financing 23
Celator Pharma Secures US$3 Million In Venture Financing 24
Partnerships 25
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 25
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 26
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 28
Celator Pharma Extends Research Agreement With Cephalon 29
Merger 30
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 30
Licensing Agreements 32
Jazz Pharma Enters into License Agreement with XL-protein 32
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 33
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 34
Jazz Pharma Enters into Licensing Agreement with Pfenex 36
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 38
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 39
Gentium Enters Into Licensing Agreement With Medison Pharma For Defibrotide 40
Equity Offering 41
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43
Debt Offering 45
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46
Asset Transactions 47
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 47
Aytu BioScience Acquires ProstaScint from Jazz Pharma 48
Essex Bidco Acquires Assets from Jazz Pharma 49
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 51
Meda Completes Acquisition Of Women’s Health Business From Jazz Pharma For US$95 Million 52
Acquisition 54
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 54
Jazz Pharma Acquires Alize Pharma 56
AstraZeneca May Acquire Ariad Pharma 57
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 59
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 61
Jazz Pharmaceuticals Plc – Key Competitors 64
Jazz Pharmaceuticals Plc – Key Employees 65
Jazz Pharmaceuticals Plc – Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Recent Developments 68
Financial Announcements 68
Nov 07, 2017: Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results 68
Aug 08, 2017: Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results 69
May 09, 2017: Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results 70
Feb 28, 2017: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results 72
Aug 09, 2016: Jazz Pharmaceuticals Announces Second Quarter 2016 Financial Results 74
May 10, 2016: Jazz Pharmaceuticals Announces First Quarter 2016 Financial Results 76
Feb 23, 2016: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results 77
Corporate Communications 79
Dec 04, 2017: Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer 79
Product News 80
11/07/2016: Jazz Pharmaceuticals to Present New Data on Defitelio at the Annual ASH Meeting 80
08/02/2016: CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation 82
03/30/2016: Jazz Pharmaceuticals Announces Webcast for Defitelio (defibrotide sodium) Investor Update 83
Product Approvals 84
Mar 30, 2016: FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow 84
Clinical Trials 85
Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients 85
Feb 18, 2016: Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting 86
Feb 01, 2016: Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD 88
Other Significant Developments 89
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 89
Appendix 90
Methodology 90
About GlobalData 90
Contact Us 90
Disclaimer 90

List of Tables
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2011 to YTD 2017 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 16
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 18
Arrivo BioVentures Raises USD49 Million in Venture Financing 19
Alize Pharma Raises USD1.9 Million in Venture Financing 20
Alize Pharma Raises USD6.4 Million in Series A Financing 21
Celator Pharma Raises US$39 Million In Venture Financing 22
Alize Pharma Raises US$4 Million In Venture Financing 23
Celator Pharma Secures US$3 Million In Venture Financing 24
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 25
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 26
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 28
Celator Pharma Extends Research Agreement With Cephalon 29
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 30
Jazz Pharma Enters into License Agreement with XL-protein 32
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 33
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 34
Jazz Pharma Enters into Licensing Agreement with Pfenex 36
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 38
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 39
Gentium Enters Into Licensing Agreement With Medison Pharma For Defibrotide 40
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 47
Aytu BioScience Acquires ProstaScint from Jazz Pharma 48
Essex Bidco Acquires Assets from Jazz Pharma 49
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 51
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 52
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 54
Jazz Pharma Acquires Alize Pharma 56
AstraZeneca May Acquire Ariad Pharma 57
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 59
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 61
Jazz Pharmaceuticals Plc, Key Competitors 64
Jazz Pharmaceuticals Plc, Key Employees 65
Jazz Pharmaceuticals Plc, Other Locations 66
Jazz Pharmaceuticals Plc, Subsidiaries 66

★海外企業調査レポート[Jazz Pharmaceuticals Plc (JAZZ)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • XBiotech Inc (XBIT)：製薬・医療：M&Aディール及び事業提携情報
    Summary XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company provides monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed …
  • Orliman SLU-医療機器分野：企業M&A・提携分析
    Summary Orliman SLU (Orliman), a subsidiary of The Riverside Company is a medical device company that develops and manufactures orthopedic products. The company's products include stabilizers, immobilizers, lumbosacral back supports, abdominal bands, abdominal belt, shoulder supports, truss, corsets …
  • W. L. Gore & Associates Inc：企業の戦略的SWOT分析
    W. L. Gore & Associates Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Cellmid Ltd (CDY)：企業の財務・戦略的SWOT分析
    Summary Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd, is a life sciences company that develops and commercializes diagnostic and therapeutic products. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such a …
  • FMR LLC：企業の戦略的SWOT分析
    FMR LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • ID Pharma Co Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary ID Pharma Co Ltd (ID Pharma), formerly DNAVEC Corp is a manufacturer and commercializer of gene medicines. The company develops regenerative medicines, cell therapy and other bio products. It provides vector platforms such as Sendai virus vector in its drug development process. ID Pharma’s v …
  • Ignyta Inc (RXDX)-製薬・医療分野：企業M&A・提携分析
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc is a drug manufacturing company that discovers, develops and commercializes new drugs targeting activated genes in cancer cells for the treatment of cancer patients. The company develops products using integrated therapeutic (Rx) and companion diagnost …
  • Nevro Corp (NVRO)：企業の財務・戦略的SWOT分析
    Summary Nevro Corp (Nevro) is a medical device company which focuses on providing novel products that advance the quality of life of people suffering from chronic pain. The company has developed Nevro Senza spinal cord stimulation (SCS) system, a non-pharmacologic neuromodulation platform for the tr …
  • Yanlord Land Group Ltd：企業の戦略・SWOT・財務情報
    Yanlord Land Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Yanlord Land Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Mochida Pharmaceutical Co Ltd (4534)：企業の財務・戦略的SWOT分析
    Mochida Pharmaceutical Co Ltd (4534) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • HeartSciences：医療機器：M&Aディール及び事業提携情報
    Summary HeartSciences, formerly Heart Test Laboratories Inc, is a medical device company that offers cardiac care products. The company develops, manufactures and markets cardiac testing tools for the early detection of heart disease. It offers MyoVista, a screening tool used to determine the presen …
  • Mizuho Financial Group Inc：企業の戦略・SWOT・財務情報
    Mizuho Financial Group Inc - Strategy, SWOT and Corporate Finance Report Summary Mizuho Financial Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Fortune Electric Co Ltd (1519)：企業の財務・戦略的SWOT分析
    Summary Fortune Electric Co Ltd (Fortune Electric) is a power company that manufactures and markets transformers and accessories. The company provides products such as distribution transformers, power transformers, cast resin transformers and amorphous metal alloy core transformers, among others. It …
  • ConSynance Therapeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary ConSynance Therapeutics Inc (ConSynance Therapeutics) is a drug discovery company that concentrates on the development of new therapeutic solutions for unmet medical needs. The company’s pipeline programs include CSTI-100, CSTI-200, and CSTI-300 among others. It develops pipeline programs fo …
  • Wolverine World Wide Inc (WWW)：企業の財務・戦略的SWOT分析
    Wolverine World Wide Inc (WWW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Antisense Therapeutics Ltd (ANP)：製薬・医療：M&Aディール及び事業提携情報
    Summary Antisense Therapeutics Ltd (Antisense Therapeutics) is clinical staged biopharmaceutical company which focuses on the discovery, development and commercialization of second generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs. It focuses on …
  • Gadeta BV：製薬・医療：M&Aディール及び事業提携情報
    Summary Gadeta BV (Gadeta) is a biotechnology company, which focuses on the research and development of cellular immunotherapies for the elimination of cancer. The company’s technology platform combines alpha beta T cells engineered to express defined Gamma Delta T cell receptors (TEGs) that demonst …
  • Netmedia S.A.：企業の戦略・SWOT・財務分析
    Netmedia S.A. - Strategy, SWOT and Corporate Finance Report Summary Netmedia S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Pacific Scientific Energetic Materials Company：企業の戦略・SWOT・財務分析
    Pacific Scientific Energetic Materials Company - Strategy, SWOT and Corporate Finance Report Summary Pacific Scientific Energetic Materials Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • The Binding Site Group Ltd：企業の製品パイプライン分析2018
    Summary The Binding Site Group Ltd (Binding Site) is a clinical diagnostic tools supplier that concentrates on research, development, manufacturing and distribution of immunodiagnostic assays. The company provides product portfolio such as antibodies, antigens, bulk antisera, assays for plasma prote …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆